肺癌患者血浆检测肿瘤标志物的分析方法及展望(4)
[8]Malapelle U， Mayo de-Las-Casas C，Rocco D，et al.Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients[J].Br J Cancer，2017，116(6)：802-810.
[9]Pantel K，Speicher MR.The biology of circulating tumor cells[J].Oncogene，2016，35(10)：1216-1224.
[10]Rolfo C，Giallombardo M，Reclusa P，et al.Exosomes in lung cancer liquid biopsies：two sides of the same coin？[J].Lung Cancer，2017(104)：134-135.
, 百拇医药
[11]Crowley E，Di Nicolantonio F，Loupakis F，et al.Liquid biopsy： monitoring cancergenetics in the blood[J].Nat Rev Clin Oncol，2013，10(8)：472-484.
[12]Mead R，Duku M，Bhandari P，et al.Circulating tumour markers can define patients with normal colons， benign polyps， and cancers[J].Br J Cancer，2011，105(2)：239-245.
[13]Normanno N，Denis MG，Thress KS，et al.Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-smallcell lung cancer[J].Oncotarget，2017，8(7)：12501-12516.
, http://www.100md.com
[14]Toro PV，Erlanger B，Beaver JA，et al.Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA[J].Clin Biochem，2015，48(15)：993-998.
[15]Schmidt B，Reinicke D，Reindl I，et al.Liquid biopsy-Performance of the PAXgene Blood ccfDNA Tubes for the isolation and characterization of cell-free plasma DNA from tumor patients[J]. Clin Chim Acta，2017(469)：94-98.
[16]Page K，Guttery DS，Zahra N，et al.Influence of plasma processing on recovery and analysis of circulating nucleic acids[J].PLoS One，2013，8(10)：e77963.
, http://www.100md.com
[17]Tie J，Kinde I，Wang Y，et al.Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer[J].Ann Oncol，2015，26(8)：1715-1722.
[18]Mauger F，Dulary C，Daviaud C，et al.Comprehensive evaluation of methods to isolate， quantify， and characterize circulating cell-free DNA from small volumes of plasma[J].Anal Bioanal Chem，2015，407(22)：6873-6878.
[19]Mayo-de-Las-Casas C，Garzón Ibánez M，Jordana-Ariza N，et al.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer[J].Expert Rev Mol Diagn，2018，18(1)：35-45.
, 百拇医药
[20]Douillard JY，Ostoros G，Cobo M，et al.Gefitinib treatment in EGFR mutated caucasian NSCLC：circulating-free tumor DNA as a surrogate for determination of EGFR status[J].J Thorac Oncol，2014，9(9)：1345-1353.
[21]Kimura H，Kasahara K，Kawaishi M，et al.Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer[J].Clin Cancer Res，2006，12(13)：3915-3921., http://www.100md.com(魏优蕾 郭晓彤)
[9]Pantel K，Speicher MR.The biology of circulating tumor cells[J].Oncogene，2016，35(10)：1216-1224.
[10]Rolfo C，Giallombardo M，Reclusa P，et al.Exosomes in lung cancer liquid biopsies：two sides of the same coin？[J].Lung Cancer，2017(104)：134-135.
, 百拇医药
[11]Crowley E，Di Nicolantonio F，Loupakis F，et al.Liquid biopsy： monitoring cancergenetics in the blood[J].Nat Rev Clin Oncol，2013，10(8)：472-484.
[12]Mead R，Duku M，Bhandari P，et al.Circulating tumour markers can define patients with normal colons， benign polyps， and cancers[J].Br J Cancer，2011，105(2)：239-245.
[13]Normanno N，Denis MG，Thress KS，et al.Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-smallcell lung cancer[J].Oncotarget，2017，8(7)：12501-12516.
, http://www.100md.com
[14]Toro PV，Erlanger B，Beaver JA，et al.Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA[J].Clin Biochem，2015，48(15)：993-998.
[15]Schmidt B，Reinicke D，Reindl I，et al.Liquid biopsy-Performance of the PAXgene Blood ccfDNA Tubes for the isolation and characterization of cell-free plasma DNA from tumor patients[J]. Clin Chim Acta，2017(469)：94-98.
[16]Page K，Guttery DS，Zahra N，et al.Influence of plasma processing on recovery and analysis of circulating nucleic acids[J].PLoS One，2013，8(10)：e77963.
, http://www.100md.com
[17]Tie J，Kinde I，Wang Y，et al.Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer[J].Ann Oncol，2015，26(8)：1715-1722.
[18]Mauger F，Dulary C，Daviaud C，et al.Comprehensive evaluation of methods to isolate， quantify， and characterize circulating cell-free DNA from small volumes of plasma[J].Anal Bioanal Chem，2015，407(22)：6873-6878.
[19]Mayo-de-Las-Casas C，Garzón Ibánez M，Jordana-Ariza N，et al.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer[J].Expert Rev Mol Diagn，2018，18(1)：35-45.
, 百拇医药
[20]Douillard JY，Ostoros G，Cobo M，et al.Gefitinib treatment in EGFR mutated caucasian NSCLC：circulating-free tumor DNA as a surrogate for determination of EGFR status[J].J Thorac Oncol，2014，9(9)：1345-1353.
[21]Kimura H，Kasahara K，Kawaishi M，et al.Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer[J].Clin Cancer Res，2006，12(13)：3915-3921., http://www.100md.com(魏优蕾 郭晓彤)